{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:23:06Z","timestamp":1771464186860,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00198-020-05676-7","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T12:02:51Z","timestamp":1602763371000},"page":"2485-2491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review"],"prefix":"10.1007","volume":"31","author":[{"given":"C.","family":"Camponovo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"O.","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6008","authenticated-orcid":false,"given":"E.","family":"Gonzalez Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"5676_CR1","doi-asserted-by":"publisher","unstructured":"Bone, HG, Bolognese, MA, Yuen, CK, Kendler, DL, Miller, PD, Yang, YC, Grazette, L, San Martin, J, and Gallagher, JC Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011;96(4):972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","DOI":"10.1210\/jc.2010-1502"},{"issue":"5","key":"5676_CR2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27(5):1917\u20131921. https:\/\/doi.org\/10.1007\/s00198-015-3458-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"5676_CR3","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O (2016) Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact 16(1):24\u201332","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"7","key":"5676_CR4","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","volume":"27","author":"AS Koldkjaer Solling","year":"2016","unstructured":"Koldkjaer Solling AS, Harslof T, Kaal A, Rejnmark L, Langdahl B (2016) Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int 27(7):2383\u20132386. https:\/\/doi.org\/10.1007\/s00198-016-3535-5","journal-title":"Osteoporos Int"},{"issue":"6","key":"5676_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pbc.25393","volume":"62","author":"N Gossai","year":"2015","unstructured":"Gossai N, Hilgers MV, Polgreen LE, Greengard EG (2015) Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer 62(6):1078\u20131080. https:\/\/doi.org\/10.1002\/pbc.25393","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"5676_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","volume":"34","author":"N Setsu","year":"2016","unstructured":"Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, Horiuchi K (2016) Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab 34(1):118\u2013122. https:\/\/doi.org\/10.1007\/s00774-015-0677-z","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"5676_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1210\/jc.2017-02025","volume":"103","author":"S Uday","year":"2018","unstructured":"Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, Sutton D, Grimer R, Hogler W (2018) Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab 103(2):596\u2013603. https:\/\/doi.org\/10.1210\/jc.2017-02025","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"5676_CR8","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"AM Boyce","year":"2012","unstructured":"Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(7):1462\u20131470. https:\/\/doi.org\/10.1002\/jbmr.1603","journal-title":"J Bone Miner Res"},{"issue":"8","key":"5676_CR9","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1210\/jc.2013-1143","volume":"98","author":"C Grasemann","year":"2013","unstructured":"Grasemann C, Schundeln MM, Hovel M, Schweiger B, Bergmann C, Herrmann R, Wieczorek D, Zabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget\u2019s disease. J Clin Endocrinol Metab 98(8):3121\u20133126. https:\/\/doi.org\/10.1210\/jc.2013-1143","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5676_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","volume":"15","author":"AM Boyce","year":"2017","unstructured":"Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15(4):283\u2013292. https:\/\/doi.org\/10.1007\/s11914-017-0380-1","journal-title":"Curr Osteoporos Rep"},{"issue":"10","key":"5676_CR11","doi-asserted-by":"publisher","first-page":"e10210","DOI":"10.1002\/jbm4.10210","volume":"3","author":"A Upfill-Brown","year":"2019","unstructured":"Upfill-Brown A, Bukata S, Bernthal NM, Felsenfeld AL, Nelson SD, Singh A, Wesseling-Perry K, Eilber FC, Federman NC (2019) Use of denosumab in children with osteoclast bone dysplasias: report of three cases. JBMR Plus 3(10):e10210. https:\/\/doi.org\/10.1002\/jbm4.10210","journal-title":"JBMR Plus"},{"key":"5676_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bone.2018.12.012","volume":"120","author":"S Roux","year":"2019","unstructured":"Roux S, Massicotte MH, Huot Daneault A, Brazeau-Lamontagne L, Dufresne J (2019) Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: case report and brief literature review. Bone 120:482\u2013486. https:\/\/doi.org\/10.1016\/j.bone.2018.12.012","journal-title":"Bone"},{"key":"5676_CR13","doi-asserted-by":"publisher","unstructured":"Uchida T, Yamaguchi H, Kushima C, Yonekawa T, Nakazato M (2019) Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab. Endocr J. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0198","DOI":"10.1507\/endocrj.EJ19-0198"},{"key":"5676_CR14","unstructured":"Tjelum L, Eiken P (2018) Multiple vertebral fractures after denosumab discontinuation. Ugeskr Laeger 180(45) https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30404716"},{"issue":"1","key":"5676_CR15","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward L (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18(1):76\u201380","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"5676_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12891-019-2855-y","volume":"20","author":"HR Durr","year":"2019","unstructured":"Durr HR, Grahneis F, Baur-Melnyk A, Knosel T, Birkenmaier C, Jansson V, Klein A (2019) Aneurysmal bone cyst: results of an off label treatment with denosumab. BMC Musculoskelet Disord 20(1):456. https:\/\/doi.org\/10.1186\/s12891-019-2855-y","journal-title":"BMC Musculoskelet Disord"},{"issue":"12","key":"5676_CR17","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/s1470-2045(19)30663-1","volume":"20","author":"S Chawla","year":"2019","unstructured":"Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E (2019) Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 20(12):1719\u20131729. https:\/\/doi.org\/10.1016\/s1470-2045(19)30663-1","journal-title":"Lancet Oncol"},{"issue":"3","key":"5676_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1574886313666180608080355","volume":"13","author":"EE Mazokopakis","year":"2018","unstructured":"Mazokopakis EE (2018) Denosumab-induced normocalcemic hyperparathyroidism in a woman with postmenopausal osteoporosis and normal renal function. Curr Drug Saf 13(3):214\u2013216. https:\/\/doi.org\/10.2174\/1574886313666180608080355","journal-title":"Curr Drug Saf"},{"issue":"3","key":"5676_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/jgs.15250","volume":"66","author":"C Eller-Vainicher","year":"2018","unstructured":"Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M, Falchetti A, Chiodini I (2018) Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 66(3):518\u2013524. https:\/\/doi.org\/10.1111\/jgs.15250","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"5676_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","volume":"8","author":"JS Leere","year":"2020","unstructured":"Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, Brondum Frokjaer J, Vestergaard P (2020) Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 8(5):407\u2013417. https:\/\/doi.org\/10.1016\/S2213-8587(20)30063-2","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05676-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05676-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05676-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T03:09:52Z","timestamp":1634267392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05676-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5676"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05676-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}